^
BIOMARKER:

SAMHD1 expression

i
Other names: SAMHD1, SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1, Monocyte Protein 5, MOP-5, Deoxynucleoside Triphosphate Triphosphohydrolase SAMHD1, SAM Domain And HD Domain-Containing Protein 1,Dendritic Cell-Derived IFNG-Induced Protein, SAM Domain And HD Domain 1, HSAMHD1, DNTPase, SBBI88, HDDC1, DCIP, Aicardi-Goutieres Syndrome 5, HD Domain Containing 1, SAMHD1, CHBL2, Mg11, AGS5, MOP5
Entrez ID:
Related biomarkers:
9d
TARGETING SAMHD1 WITH HYDROXYUREA IN FIRST-LINE CYTARABINE-BASED THERAPY OF NEWLY DIAGNOSED ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE HEAT-AML TRIAL (EHA 2022)
Patients with CBF-AML eligible for treatment with gemtuzumab-ozogamicin were excluded...on day 1-5 during all 4 cycles and daunorubicin 60 mg/m 2 i.v. q.d. on day 1-3 during cycles 1 and 2, and on day 1-2 during cycle 3. Patients with FLT3 -mutated AML received midostaurin 50 mg b.i.d...Importantly, orally administered hydroxyurea may provide a safe, inexpensive, and broadly accessible strategy to improve outcome in AML. These results will have to be validated in a larger patient cohort.
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1) • CD68 (CD68 Molecule)
|
FLT3 mutation • SAMHD1 expression
|
cytarabine • Rydapt (midostaurin) • daunorubicin • Mylotarg (gemtuzumab ozogamicin) • hydroxyurea
3ms
Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. (PubMed, Cancers (Basel))
In vitro treatment with platinum-derived drugs significantly enhanced γ-H2AX and apoptotic markers expression in knock-out cells, indicating a synergic effect of SAMHD1 depletion and platinum-based treatment. SAMHD1 expression represents a new strong prognostic and predictive biomarker in solid tumors and, thus, modulation of the SAMHD1 function may constitute a promising target for the improvement of cancer therapy.
Journal
|
SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1)
|
SAMHD1 expression
5ms
SAMHD1 Mutations and Expression in Mantle Cell Lymphoma Patients. (PubMed, Front Oncol)
SAMHD1 was also reported as a barrier to cytarabine, a common chemotherapy drug for mantle cell lymphoma (MCL), and as a biomarker of grim prognosis for acute myelocytic leukemia (AML) patients...The mutations had not been found to corelate with SAMHD1 protein expression detected by immunohistochemistry. The biological functions of this mutated SAMHD1 remain to be investigated.
Clinical • Journal
|
SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1) • CASP3 (Caspase 3)
|
SAMHD1 expression • SAMHD1 mutation
|
cytarabine
7ms
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. (PubMed, Virchows Arch)
We hypothesized that expression of SAMHD1 could predict short time to progression in patients treated with Cytarabine as part of high-dose chemotherapy. Despite the correlation with known biological adverse prognostic factors, neither low or high SAMHD1 expression correlated to PFS or OS in patients treated according to the Nordic MCL2 or MCL3 protocols (N = 158).
Clinical • Journal
|
SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1) • SOX11 (SRY-Box Transcription Factor 11)
|
SAMHD1 expression • SOX11 expression
|
cytarabine
7ms
Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML (ASH 2021)
Other nucleoside analogs, such as clofarabine, fludarabine, and gemcitabine have also been shown to be substrates of SAMHD1 (PMID:30305425)...Another 3’UTR SNP, rs1291128 was associated with poor OS in AML02 and in the clofarabine plus ara-C treatment arm in AML08 trial...Future studies are aimed at looking at haplotypes and SNP-SNP combinations to establish the impact SAMHD1 pharmacogenomics on its expression within leukemic cells and subsequent response to nucleoside analogs in AML patients. SAMHD1 has also been implicated as a tumor suppressor; thus, future studies will evaluate its role both as a proliferation regulator and in drug resistance.
Clinical • Clinical data
|
SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1)
|
SAMHD1 expression
|
gemcitabine • cytarabine • clofarabine • fludarabine IV
11ms
Analysis of SAMHD1 Restriction by Flow Cytometry in Human Myeloid U937 Cells. (PubMed, J Vis Exp)
Equally, the susceptibility of different tester viruses can be determined. The assay can be further adapted to incorporate the effect of differentiation status, metabolic status, and SAMHD1 modifiers to better understand the relationship between SAMHD1, cell metabolic state, and viral restriction.
Journal
|
SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1)
|
SAMHD1 expression